Orexo wins French and Spanish approvals for pain drug
Abstral is expected to be launched during the second half of 2009 in France and Spain, following pricing and reimbursement negotiations with the relevant authorities, by ProStrakan, Orexo’s
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.